NASDAQ:GRCL - Gracell Biotechnologies Stock Price Target and Predictions

  • Consensus Rating: Buy
  • Consensus Price Target: $34.50
  • Forecasted Upside: 162.56 %
  • Number of Analysts: 4
  • Breakdown:
  • 0 Sell Ratings
  • 0 Hold Ratings
  • 4 Buy Ratings
  • 0 Strong Buy Ratings
$13.14
▼ -0.1 (-0.76%)

This chart shows the closing price for GRCL by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New Gracell Biotechnologies Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for GRCL and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for GRCL

Analyst Price Target is $34.50
▲ +162.56% Upside Potential
This price target is based on 4 analysts offering 12 month price targets for Gracell Biotechnologies in the last 3 months. The average price target is $34.50, with a high forecast of $40.00 and a low forecast of $30.00. The average price target represents a 162.56% upside from the last price of $13.14.

This chart shows the closing price for GRCL for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart

Current Consensus is Buy

The current consensus among 4 investment analysts is to buy stock in Gracell Biotechnologies.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/26/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/25/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/23/2020
  • 0 strong buy ratings
  • 0 buy ratings
  • 0 hold ratings
  • 0 sell ratings
1/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
4/21/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
7/20/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
9/18/2021
  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings
10/18/2021

Latest Recommendations

  • 0 strong buy ratings
  • 4 buy ratings
  • 0 hold ratings
  • 0 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetImpact on Share PriceDetails
2/3/2021CitigroupInitiated CoverageBuy$35.00High
2/2/2021Jefferies Financial GroupInitiated CoverageBuy$30.00Low
2/2/2021Piper SandlerInitiated CoverageOverweight$40.00N/A
2/2/2021Wells Fargo & CompanyInitiated CoverageOverweight$33.00N/A
(Data available from 10/18/2016 forward)

News Sentiment Rating

0.21 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 0 very positive mentions
  • 2 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
3/22/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
4/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
5/21/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
6/20/2021
  • 1 very positive mentions
  • 1 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
7/20/2021
  • 1 very positive mentions
  • 3 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
8/19/2021
  • 0 very positive mentions
  • 0 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
9/18/2021
  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions
10/18/2021

Current Sentiment

  • 0 very positive mentions
  • 5 positive mentions
  • 1 negative mentions
  • 0 very negative mentions

Recent Stories by Sentiment

Very Negative

  • No very negative mentions tracked during this time.

Very Positive

  • No very positive mentions tracked during this time.
Gracell Biotechnologies logo
Gracell Biotechnologies Inc., a clinical-stage biopharmaceutical company, primarily discovers and develops cell therapies for the treatment of cancer in the People's Republic of China. Its lead product candidates include GC012F, a FasTCAR-enabled dual BCMA- and CD19-directed autologous CAR-T product candidate that is in Phase I trial for the treatment of multiple myeloma; GC019F, a FasTCAR-enabled CD19-directed autologous CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult B cell acute lymphoblastic leukemia (B-ALL), as well as in preclinical stage for the treatment of relapsed or refractory (r/r) B cell non-Hodgkin's lymphoma (B-NHL); and GC027, a TruUCAR-enabled CD7-directed allogeneic CAR-T product candidate, which is in Phase I clinical trial for the treatment of adult T cell acute lymphoblastic leukemia. The company's product candidates also comprise; and GC007g, a donor-derived CD19-directed allogeneic CAR-T cell therapy that is in Phase I clinical trial for the treatment of r/r B-ALL. In addition, it has a portfolio of earlier stage product candidates targeting various cancer indications, such as ovarian cancer, breast cancer, peripheral T cell lymphoma, a subtype of NHL, and T cell lymphoblastic leukemia. The company was founded in 2017 and is headquartered in Suzhou, China.
Read More

Today's Range

Now: $13.14
Low: $13.14
High: $13.14

50 Day Range

MA: $12.38
Low: $9.91
High: $14.90

52 Week Range

Now: $13.14
Low: $9.75
High: $33.70

Volume

100 shs

Average Volume

118,654 shs

Market Capitalization

$883.59 million

P/E Ratio

N/A

Dividend Yield

N/A

Beta

N/A

Frequently Asked Questions

What sell-side analysts currently cover shares of Gracell Biotechnologies?

The following equities research analysts have issued research reports on Gracell Biotechnologies in the last year: Citigroup Inc., Jefferies Financial Group Inc., Piper Sandler, Wells Fargo & Company, and Zacks Investment Research.
View the latest analyst ratings for GRCL.

What is the current price target for Gracell Biotechnologies?

4 Wall Street analysts have set twelve-month price targets for Gracell Biotechnologies in the last year. Their average twelve-month price target is $34.50, suggesting a possible upside of 162.6%. Piper Sandler has the highest price target set, predicting GRCL will reach $40.00 in the next twelve months. Jefferies Financial Group Inc. has the lowest price target set, forecasting a price of $30.00 for Gracell Biotechnologies in the next year.
View the latest price targets for GRCL.

What is the current consensus analyst rating for Gracell Biotechnologies?

Gracell Biotechnologies currently has 4 buy ratings from Wall Street analysts. The stock has a consensus analyst rating of "Buy." A "buy" rating indicates that analysts believe GRCL will outperform the market and that investors should add to their positions of Gracell Biotechnologies.
View the latest ratings for GRCL.

How do I contact Gracell Biotechnologies' investor relations team?

The company's listed phone number is 86-512-6262-6701 and its investor relations email address is [email protected] The official website for Gracell Biotechnologies is www.gracellbio.com.